Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.
作者信息
Kow Chia Siang, Aldeyab Mamoon, Hasan Syed Shahzad
机构信息
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom.
出版信息
Eur J Clin Pharmacol. 2021 Mar;77(3):435-437. doi: 10.1007/s00228-020-03008-6. Epub 2020 Oct 4.
Abstract
摘要
相似文献
1
Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.瑞德西韦用于新冠肺炎患者临床试验中不良事件报告的质量
Eur J Clin Pharmacol. 2021 Mar;77(3):435-437. doi: 10.1007/s00228-020-03008-6. Epub 2020 Oct 4.
2
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
3
Remdesivir (Veklury) for COVID-19.用于治疗新冠肺炎的瑞德西韦（Veklury）
Med Lett Drugs Ther. 2020 Nov 30;62(1612):186-188.
4
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.使用真实世界数据评估瑞德西韦治疗 2019 冠状病毒病相关不良反应。
Expert Opin Drug Saf. 2021 Dec;20(12):1559-1564. doi: 10.1080/14740338.2021.1962846. Epub 2021 Aug 5.
5
Safety profile of the antiviral drug remdesivir: An update.抗病毒药物瑞德西韦的安全性概况：最新情况
Biomed Pharmacother. 2020 Oct;130:110532. doi: 10.1016/j.biopha.2020.110532. Epub 2020 Jul 22.
6
Remdesivir for patients with COVID-19.瑞德西韦用于治疗新冠肺炎患者。
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
7
Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.一名59岁男性在接受瑞德西韦治疗新型冠状病毒肺炎时出现心动过缓。
CMAJ. 2021 Apr 26;193(17):E612-E615. doi: 10.1503/cmaj.210300.
8
Remdesivir for the treatment of COVID-19 in pregnancy.瑞德西韦用于治疗妊娠期新型冠状病毒肺炎
J Med Virol. 2021 Jul;93(7):4114-4119. doi: 10.1002/jmv.26986. Epub 2021 Apr 14.
9
Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.瑞德西韦致新型冠状病毒肺炎患者心动过缓：一项单中心前瞻性研究
Circ Arrhythm Electrophysiol. 2021 Jul;14(7):e009811. doi: 10.1161/CIRCEP.121.009811. Epub 2021 Jun 29.
10
COVID-19 update: Remdesivir (Veklury) FDA-approved for children <12 years old.新冠疫情最新消息：瑞德西韦（Veklury）获美国食品药品监督管理局批准用于12岁以下儿童。
Med Lett Drugs Ther. 2022 Jun 13;64(1652):e1.
引用本文的文献
1
Pharmacovigilance Concept Knowledge, Perspectives and Attitudes: A Cross-Sectional Study Among Community Pharmacists.药物警戒概念知识、观点和态度：社区药剂师的横断面研究。
Inquiry. 2024 Jan-Dec;61:469580241246464. doi: 10.1177/00469580241246464.
2
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review.新冠病毒疾病药物临床试验中不良事件报告的质量：系统评价
BMJ Med. 2023 Sep 21;2(1):e000352. doi: 10.1136/bmjmed-2022-000352. eCollection 2023.
3
Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.瑞德西韦与新型冠状病毒肺炎患者窦性心动过缓的相关性：一项前瞻性纵向研究。
Front Pharmacol. 2023 Jan 17;13:1107198. doi: 10.3389/fphar.2022.1107198. eCollection 2022.
4
Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019-The pilot study.瑞德西韦可能会使2019冠状病毒病患者的心电图出现除心动过缓之外的变化——一项初步研究。
J Med Virol. 2021 Oct;93(10):5724-5725. doi: 10.1002/jmv.27177. Epub 2021 Jul 14.
5
Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).瑞德西韦治疗2019冠状病毒病（COVID-19）患者与短暂性心动过缓
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.025. Epub 2021 May 28.
6
Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids.机器学习作为一种精准医疗方法用于开具瑞德西韦或皮质类固醇治疗新冠肺炎的药物处方
Clin Ther. 2021 May;43(5):871-885. doi: 10.1016/j.clinthera.2021.03.016. Epub 2021 Mar 29.
7
Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者中与瑞德西韦相关的潜在短暂性心动过缓
J Med Virol. 2021 May;93(5):2631-2634. doi: 10.1002/jmv.26898. Epub 2021 Mar 3.
本文引用的文献
1
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响：一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
2
Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature.瑞德西韦诱发的对称性药物相关性擦烂和屈侧疹（SDRIFE）？一例病例报告并文献复习
Eur J Clin Pharmacol. 2021 Jan;77(1):141-144. doi: 10.1007/s00228-020-02955-4. Epub 2020 Aug 6.
3
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
4
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.新型冠状病毒疾病 2019 患者的药物性肝损伤：瑞德西韦与 P-糖蛋白抑制剂的潜在相互作用。
Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.
5
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
6
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
7
Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic review.类风湿关节炎药物干预随机对照试验中危害报告的质量：一项系统评价
Evid Based Med. 2017 Oct;22(5):170-177. doi: 10.1136/ebmed-2017-110715. Epub 2017 Sep 2.
8
Better reporting of harms in randomized trials: an extension of the CONSORT statement.随机试验中不良事件的更好报告：CONSORT声明的扩展
Ann Intern Med. 2004 Nov 16;141(10):781-8. doi: 10.7326/0003-4819-141-10-200411160-00009.
Zotero 插件